Qualifying Therapeutic Discovery Project Grants for the State of Colorado
OctoberThe listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Accelr8 Technology Corporation | BACcel Rapid Diagnostic | $ 244,479.24 | |
| Actium Biosystems, LLC | Electromagnetic radio frequency excitation of nanoparticles for the external, non-invasive treatment of cancer via physical means. | $ 244,479.25 | |
| Allos Therapeutics, Inc | Pralatrexate for the Treatment of Relapsed/Refractory Cutaneous T-cell Lyphoma (CTCL) | $ 244,479.24 | |
| Allos Therapeutics, Inc | Pralatrexate for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | $ 244,479.24 | |
| Allos Therapeutics, Inc | Pralatrexate as treatment for urinary bladder trasitional cell carcinomas (TCCs). | $ 244,479.24 | |
| Allos Therapeutics, Inc | Pralatrexate for the Treatment of Advanced Non-small Cell lung Cancer (NSCLC) | $ 244,479.24 | |
| Allos Therapeutics, Inc | Pralatrexate for the Treatment of Advanced/Metastatic Breast Cancer | $ 244,479.24 | |
| Allos Therapeutics, Inc. | Pralatrexate for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma | $ 244,479.24 | |
| ApopLogic Pharmaceuticals, Inc | AP-300 to treat superficial bladder cancer | $ 105,313.00 | |
| ApopLogic Pharmaceuticals, Inc. | B201-acetate to treat small lung cancer and other hard to treat cancers | $ 201,419.00 | $ 3,032.50 |
| Aqueous Biomedical Inc. | Oculieve glaucoma shunt development | $ 70,736.52 | $ 155,000.00 |
| ARCA Biopharma Inc | Gencaro (Bucindolol) CHF Therapeutic | $ 244,479.25 | |
| ARCA biopharma, Inc | NU172 Short-acting anticoagulant for cardiac procedures. | $ 244,479.25 | |
| ArcScan, Inc. | Artemis 3 | $ 244,479.25 | |
| AspenBio Pharma Inc | AppyScore™ | $ 244,479.25 | |
| Beacon Biotechnology LLC | BrightSPOT diagnostic technology | $ 180,126.83 | $ 64,352.42 |
| BioAMPS International, Inc | Novel Therapeutics for the Treatment of Drug-resistant Bacterial Infections | $ 70,773.50 | |
| Biodesix Inc | Mass Spectrometry for Prostate Cancer Detection | $ 155,268.50 | $ 89,210.75 |
| BIODESIX INC | Researching Immunosuppressive Agents for Improved EGFR-I Therapy Effectiveness | $ 97,831.00 | $ 146,648.25 |
| Biodesix, Inc | Mass Spectrometry for Diagnosis of Inflammatory Colitis | $ 83,601.00 | $ 118,757.50 |
| BIODESIX, INC | VeriStrat® : For Guiding Epidermal Growth Factor Receptor inhibitor Therapy in Cancer | $ 244,479.25 | |
| Biodesix, Inc | Mass Spectrometry for Autoimmune Liver Disease Diagnosis | $ 101,018.50 | $ 118,757.50 |
| Biodesix, Inc. | CancerDetect: For early diagnostic of lung cancer (LC) | $ 162,120.00 | $ 82,359.25 |
| BiOptix Diagnostics, Inc. | BiOptix Accolade Project | $ 227,575.00 | $ 16,904.25 |
| Bolder Biotechnology Inc. | Novel Erythropoiesis-Stimulating Protein for Chronic Kidney Disease and Cancer | $ 41,763.53 | $ 202,715.72 |
| Bolder Biotechnology Inc. | Novel, Long-Acting Growth Hormane Analog for Treatment Short Stature and Lipodystrophy | $ 125,951.74 | $ 118,527.51 |
| Bolder Biotechnology Inc. | Novel long-acting G-CSF analog for treating acute radiation syndrome and cancer | $ 17,523.68 | $ 196,704.31 |
| Bolder Biotechnology Inc. | Novel long-acting beta interferon analog for treating multiple sclerosis and cancer | $ 119,991.28 | $ 124,487.97 |
| Bolder Biotechnology Inc. | Novel, long-acting GM-CSF analog for treating acute radiation exposure and cancer-associated neutropenia. | $ 21,682.98 | $ 222,796.27 |
| Cell Point | EC Technology | $ 244,479.24 | |
| CeMines Inc | Molecular Diagnostic Project for Lung Cancer | $ 197,725.50 | |
| Cerapedics Inc | Peptide Enhancement Anorganic Bone Mineral for Cervical Spinal Fusion Surgery | $ 244,479.24 | |
| Cerapedics Inc | Optimized Delivery Matrices for Augmenting Pluipotent {Stem} Cell Repair of Hard Tissue | $ 244,479.24 | |
| Cerapedics Inc | Lyophilized Peptide Enhanced Bone Graft Conjugates For Trauma Applications | $ 244,479.24 | |
| CereScan Corp | Development of tools to diagnose diseases and conditions of the brain | $ 244,479.25 | |
| Chata Biosystems, Inc | A Stronger, Broad Spectrum, Environmentally safe Disinfectant | $ 67,799.50 | $ 176,679.75 |
| Clovis Oncology Inc | Development of CO-1.01 and companion diagnostic test for treatment of pancreatic cancer | $ 244,479.25 | |
| Clovis Oncology, Inc. | Development of EMSI and companion diagnostic for treatment of non-small cell lung cancer | $ 244,479.25 | |
| Corgenix Medical Corporation | Determination of predictive value of AtherOx for atherosclerotic cardiovascular disease. | $ 26,250.00 | $ 72,500.00 |
| Crestone, Inc | PoIC Inhibitors as Novel herapeutics for Antibiotic-Resistant Gram-Positive Infections | $ 8,900.00 | $ 138,840.00 |
| Crestone, Inc. | REP3123 as a Novel Therapeutic for Treatment of Clostridium difficile Infection | $ 37,233.00 | $ 60,885.00 |
| EndoShape, Inc | A nonmetalic, Shape Memory Polymer AAA Endograft to expand patient applicability, etc | $ 130,608.00 | $ 109,080.50 |
| EndoShape, Inc | An SMP fallopian tube occlusion device for non-surgical, permanent female sterilization, etc | $ 61,230.00 | $ 99,954.00 |
| Eveia Medical,Inc | Development of a Coagulation Test for Clinic and Home Use | $ 244,479.25 | |
| GlobeImmune, Inc. | GI-6207 as active immunotherapy for the treatment of CEA over-expressing cancers. | $ 241,869.50 | $ 2,609.74 |
| GlobeImmune, Inc. | GI-4000 as active immunotherapy for the treatment of mutated-Ras cancers. | $ 244,479.24 | |
| Globelmmune, Inc. | GI-5005 as active immunotherapy for the treatment of chronic hepatitis C virus infection | $ 244,479.24 | |
| Greffex, Inc | Fully Deleted Helper-Virus Independent Vectors as Vaccine Carriers | $ 244,479.24 | |
| Hiberna Corporation | Python Project | $ 63,550.50 | $ 33,591.50 |
| ICVRX LLC | CNS Site Specific Medication Delivery to Improve Outcomes for Refractory Epilepsy Patients | $ 244,479.25 | |
| Inviragen, Inc | Recombinant attenuated chikungunya vaccine | $ 113,013.50 | $ 131,465.75 |
| Inviragen, Inc | A recombinant, tetravalent vaccine to prevent dengue fever | $ 244,479.25 | |
| Isogenis, Inc | Protection of Tissue & Organ Transplants by Engineered Veto | $ 244,479.24 | |
| Kestrel Labs, Inc | Noninvasive CO-Oximeter for Measuring Multiple Hemoglobin Species | $ 244,479.25 | |
| Lanx, Inc. | Biomimetic Approach for the Delivery of Bone Morphogenic Proteins | $ 119,000.00 | $ 125,479.25 |
| Leap Frogg, LLC | Frogg Dynamic Compression system (FDCS) | $ 189,969.50 | $ 54,509.75 |
| MBC Pharma Inc | Novel bone-targeted therapeutics for cancer-induced bone disease | $ 244,479.24 | |
| Micro-Imaging Solutions LLC | Rigid and Articulating-tipped (flexible), disposable CMOS-based endoscopes | $ 244,479.24 | |
| MicroPhage Inc | Deveolpment of a Novel Rapid MRSA/MSSA Blood Culture Test | $ 244,479.24 | |
| MicroPhage, Inc | Development of a Novel and Rapid Skin Tissue Antobiotic Susceptibility Test | $ 244,479.24 | |
| Miragen Therapeutics, Inc. | Developing microRNA based therapies to transform the course of Cardiovascular Disease | $ 244,479.25 | |
| Myocept, Inc | Myocept Project | $ 78,224.16 | $ 166,255.09 |
| N30 Pharmaceuticals, LLC | Inhibitors of S-nitrosoglutathione reductase (GSNOR) | $ 244,479.24 | |
| Ocutronics, LLC | OC100 | $ 76,411.00 | $ 168,068.25 |
| Otologics, LLC | Carina Project | $ 244,479.25 | |
| Parascript, LLC | AccuDetect | $ 244,479.25 | |
| PARE Surgical, Inc. | Flexible Endoscopic Instruments | $ 127,457.00 | $ 117,022.24 |
| Pathogen Systems, Inc. | Pathogenic Microbe Detection Device | $ 244,479.25 | |
| PharmaJet Inc | Novel Delivery of Drugs and Vaccines Enabled by Intradermal Jet Injection Technology | $ 91,876.26 | $ 152,602.99 |
| Precision Photonics Corp | Point-of-care(POC) diagnostic device for critical infectious disease panel testing | $ 244,479.24 | |
| ProFoldRx, Inc dba BaroFold, Inc | High Pressure Refolding of protein Aggregates for Novel Therapeutics and Biosimilars | $ 244,479.25 | |
| Protectstyle Corporation | Preventative Therapeutic Antimicrobial Textiles | $ 244,479.24 | |
| Pyxant Labs Inc | LC/MSMS Bioassay for Physiologic Iron Biomarkers | $ 27,703.45 | |
| Pyxant Labs, Inc | Trastuzumab Bioanalytical Assay for Regulatory Development Studies | $ 71,029.59 | |
| Quest Product Development Corporation | Cardiac Sync Technology for Improved CPR Therapy | $ 244,479.25 | |
| Quest Product Development Corportaion | MicroFlex Endescopes for Improved Diagnosis and Surgery | $ 244,479.25 | |
| Rocky Mountain Biosystems, Inc. | Adtivated Thermoset Adhesive for Wound Closure | $ 244,479.25 | |
| Rocky Mountain Biosystems, Inc. | Skin Patch for Drug Delivery after Controlled Stratum Corneum Ablation. | $ 29,281.00 | $ 73,049.00 |
| Somalogic Inc | A Simple Blood Test for the Early Detection of Mesothelioma | $ 130,028.00 | $ 114,451.25 |
| SomaLogic, Inc | A Simple and inexpensive Blood Test for the Early Detection of Non-Small Cell Lung Cancer | $ 244,479.25 | |
| SomaLogic, Inc | Novel Therapeutics for the Treatment of Cancer | $ 244,479.25 | |
| SomaLogic, Inc | A Simple and inexpensive Blood Test for the Early Detection of Ovarian Cancer | $ 244,479.25 | |
| SomaLogic, Inc. | A Simple Blood Test for the Early Detection of Pancreatic Cancer | $ 875.00 | $ 193,137.00 |
| SomaLogic, Inc. | Novel Neuroprotective and Neuroregenerative Therapeutics for Neurodegenerative Diseases | $ 244,479.25 | |
| SomaLogic,Inc. | Aggregation of Blood Test for Multiple Diseases into an Inexpensive Multiplexed Diagnostic | $ 244,479.25 | |
| SomaLogic. Inc | A Simple and Inexpensive Blood Test for the Early Detection of Chronic Kidney Disease | $ 86,685.50 | $ 157,793.75 |
| Sophono Inc | Sophono Alpha 1 magnetic hearing prosthesis | $ 82,120.82 | $ 162,358.43 |
| Source Precision Medicine Inc dba Source MDx | Develop & Validate a Breast Cancer Early Detection Molecular Diagnostic Test | $ 38,836.00 | $ 205,643.25 |
| Source Precision Medicine Inc dba Source MDx | Develop & Validate a Molecular Diagnostic Test Predictive of Prostate Biopsy Outcomes | $ 244,479.25 | |
| Source Precision Medicine Inc dba Source MDx | Develop & Validate a Lung Cancer Early Detectin Molecular Diagnostic Test | $ 244,479.25 | |
| St Cardio Technologies | Z6 Cardiac Stimulator | $ 186,138.50 | $ 58,340.75 |
| St. Renatus LLC | Nasal Mist Dental Anesthetic | $ 244,479.25 | |
| Sundance Diagnostics, Inc | Whole Genome Sequencing for Diagnostic Test for Suicidal Ideation | $ 244,479.25 | |
| Surefire Medical, Inc | Paladin Embolization Infusion System | $ 12,576.00 | $ 231,903.25 |
| ValveXchange, Inc | Vitality ™ and Vanguard ™ heart valve systems | $ 244,479.24 | |
| Ventria Bioscience | Development of an oral delivery platform biologics | $ 111,500.00 | $ 71,000.00 |
| Ventria Bioscience | Prevention of Antibiotic Associated Diarrhea | $ 33,938.50 | $ 210,540.75 |
| Ventria Bioscience | Treatment for spontaneous bacterial peritonitis | $ 244,479.25 | |
| Vitrolife Inc | HELP- Human Ex-Vivo Lung Preservation and Reconditioning | $ 244,479.24 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
